However, since the dual HER2-targeted approach may further improve pCR rates compared with use of either RTZ alone (19, 23, 26, 27), most patients with HER2-positive breast cancer who received neoadjuvant chemotherapy at our institutions were treated with TCHP from 2018, when CT-P6 was approved. This evidence concerns the gene ERBB2 and breast cancer.